Evecare • Vol 11 • No. 2 • Sep–Dec 2023 4 Table 2 shows the effect of Evecare forte on the clinical parameters of PCOS. There was a significant reduction in hair loss and acne after the treatment with Evecare forte Liquid. There was a reduction from the at-entry values to month-3 values in the clinical parameters depression, deepening of voice, and hirsutism. No adverse effects were reported or recorded during the study. Discussion Evecare forte Liquid is a polyherbal formulation comprising extracts of Symplocos racemosa, Trigonella foenum-graecum, Sphaeranthus indicus, Nardostachys jatamansi, and Aloe barbadensis. S racemosa is reported to reduce the high androgen level in PCOS and prevent ovarian cell dysfunction, leading to an improvement in fertility. It also helps normalize progesterone and cholesterol levels, restore the histology of the ovarian tissue, and improve ovarian and uterine weight. T foenumgraecum helps normalize the significantly high levels of LH and FSH, observed in PCOS, and thus, regularizes the menstrual cycle. S indicus is reported to have androgen receptor–inhibitory action, and thus, helps reduce the elevated testosterone level. N jatamansi possesses antiandrogenic activity, and it helps reduce the signs and symptoms associated with hyperandrogenism such as hirsutism and hyperpigmentation. A barbadensis helps normalize estrous cyclicity, maintain steroid status, and improve the fertility status. Conclusion Thus, Evecare forte Liquid is safe and effective in the management of PCOS. Evecare forte Liquid in the Management of Polycystic Ovary Syndrome Table 1. Effect of Evecare forte Liquid on Hormonal Parameters Hormonal Parameter At Entry At the End of the Study Testosterone, ng/dL 67.37 ± 22.91 35.13 ± 37.3 — aP < .0063 LH, IU/mL 14.4 ± 6.12 10.05 ± 4.92 — aP < .0435 FSH, IU/mL 7.26 ± 1.67 6.4 ± 1.75 Serum Insulin, IU/mL 31.48 ± 20.68 31.67 ± 24.77 Progesterone, ng/mL 0.4 ± 0.5 0.25 ± 0.25 Estrogen, pg/mL 98.07 ± 71.32 69.25 ± 46.88 No. of Ovarian Follicles, n 21.33 ± 4.62 17.50 ± 5.27 — aP < .0252 Size of the Follicle, mm 11.68 ± 2.46 11.24 ± 1.27 Statistical test: Paired t test Values are represented as mean ± SD. aP compared with at-entry values. Significance was fixed at < .05. FSH, follicle-stimulating hormone; LH, luteinizing hormone. Table 2. Effect of Evecare forte Liquid on the Clinical Parameters of PCOS Parameter At Entry Month 1 Month 2 Month 3 Hair Loss (n = 29) 1.38 ± 0.49 1.14 ± 0.44 0.97 ± 0.19 0.9 ± 0.31; aP < .0264 Acne (n = 20) 1.15 ± 0.49 0.75 ± 0.44 0.65 ± 0.49 0.6 ± 0.5; aP < .0423 Depression (n =14) 1.07 ± 0.27 1 ± 0 0.86 ± 0.36 0.71 ± 0.47 Deepening of Voice (n = 10) 0.9 ± 0.32 0.9 ± 0.32 0.7 ± 0.48 0.5 ± 0.53 Hirsutism (n =14) 1.29 ± 0.61 1.14 ± 0.66 0.93 ± 0.73 0.71 ± 0.83 Statistical test: Friedman's test followed by Dunn’s multiple comparisons test. Significance was fixed at < .05. Values are represented as mean ± SD. aCompared with at-entry values. PCOS, polycystic ovary syndrome. there was a reduction in the LH level and also a trend toward a decrease in the FSH level, which is indicative of improvement in PCOS. The serum progesterone and estrogen levels also reduced. These significant changes in the hormonal parameters (eg, testosterone level) indicate the benefit of Evecare forte therapy. Also, USG findings revealed that the number of ovarian follicles and the size of the ovarian follicles reduced at the end of the study.
RkJQdWJsaXNoZXIy MjAwNDg=